19 Jun 2020 15:13 (2 tahun 9 bulan lalu) -
By Junko Fujita and Rocky Swift TOKYO (Reuters) - Blackstone, Bain Capital and Taisho Pharmaceutical are among the final bidders for Takeda Pharmaceutical's (T: 4502) consumer drug business in Japan, a deal that could be worth up to 400 billion yen ($3.7 billion), three people familiar with the deal said. Japan's Taisho Pharmaceutical Holdings Co Ltd (T: 4581) is the front runner for the deal, all three people said. CVC Capital Partners is also among the final bidders, they said. The sale of Takeda Consumer Healthcare Co, known for its Alinamin line of energy drinks, is part of Takeda's efforts to shed $10 billion in non-core assets to red ...